Teleflex (NYSE:TFX) versus ENDRA Life Sciences (NASDAQ:NDRA) Head-To-Head Contrast

ENDRA Life Sciences (NASDAQ:NDRA) and Teleflex (NYSE:TFX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Volatility and Risk

ENDRA Life Sciences has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, Teleflex has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Insider and Institutional Ownership

1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 95.6% of Teleflex shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by company insiders. Comparatively, 0.7% of Teleflex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for ENDRA Life Sciences and Teleflex, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1	0	1	0	2.00
Teleflex	1	5	4	1	2.45

ENDRA Life Sciences presently has a consensus target price of $25.00, indicating a potential upside of 414.40%. Teleflex has a consensus target price of $148.00, indicating a potential upside of 12.24%. Given ENDRA Life Sciences’ higher probable upside, equities research analysts plainly believe ENDRA Life Sciences is more favorable than Teleflex.

Earnings and Valuation

This table compares ENDRA Life Sciences and Teleflex”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03 million	($8.15)	-0.60
Teleflex	$1.99 billion	2.93	-$905.64 million	($22.80)	-5.78

ENDRA Life Sciences has higher earnings, but lower revenue than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ENDRA Life Sciences and Teleflex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-433.64%	-204.58%
Teleflex	-35.88%	13.29%	6.55%

Summary

Teleflex beats ENDRA Life Sciences on 8 of the 14 factors compared between the two stocks.

About ENDRA Life Sciences

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.